Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

IGXT - Intelgenx

Discussion in 'Penny Stocks' started by Biotechmaster, Jul 19, 2016.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there is another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .

    IGXT has a ridiculous Market Cap of less than $32 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL



    Intelgenx (IGXT)

    Market Cap: $31.8 Million
    Cash: $2.1 Million
    Price: $0.49

    Burn-Rate: $400k per Quarter
    Shares Out : 63.6 Million


    •Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016

    Rizaport (Migraine)
    •European Mktg Approval–November 2015
    •Planned USA submission to FDA Q4/2016
    •Expected USA launch Q2/2017

    Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
    •505(b)(2) USA NDA submission in Q4/2016
    •Expected USA launch Q4/2017

    Indicated for Opioid Dependence
    •Awaiting FDA approval
    •According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.


    Presentation July 2016
    http://image.slidesharecdn.com/inte...sentation-july-6-2016-9-638.jpg?cb=1467900821

    [​IMG]


    [​IMG]

    [​IMG]
     
  2. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    Strong Insider & Institutional Ownership on this Goldmine . Big Jump to new highs could come anytime now .GL

    Insider Ownership :

    Horst G. Zerbe 4,670,243.5 7.34%
    Ingrid Zerbe 5,471,356.5 8.60%
    Bernard J. Boudreau 287,500
    Bernd Melcher 232,500
    Andre Godin 214,500
    Ian Troup 187,500
    John Marinucc 175,000
    Nadine Paiement 135,000
    Clemens Mayr 68,750
    John Durham 50,000
    Robert Bechard 10,000

    All directors and officers as a group (11 persons) 11,502,351 18.08%

    Institutional Holders :
    Alpha Capital ...3.2M
    Roadmap Capital Inc. 3.1M


    Insider activity

    BECHARD ROBERT J. Officer Purchase at $0.47 - $0.51 per share. Direct 4,900 Jan 22, 2016 10,000

    BOUDREAU BERNARD Director Purchase at $0.51 - $0.51 per share. Indirect 6,120 Jan 22, 2016 12,000

    BOUDREAU BERNARD Director Purchase at $0.51 - $0.51 per share. Direct 19,000 Jan 22, 2016 38,000

    BOUDREAU BERNARD Director Purchase at $0.45 - $0.45 per share. Indirect 3,375 Jan 21, 2016 7,500

    GODIN ANDRE Officer Purchase at $0.40 - $0.4 per share. Direct 8,000 Jan 20, 2016 20,000

    BOUDREAU BERNARD Director Purchase at $0.41 - $0.41 per share. Indirect 3,075 Jan 20, 2016 7,500

    GODIN ANDRE Officer Purchase at $0.52 - $0.52 per share. Direct 4,940 Dec 30, 2015 9,500

    GODIN ANDRE Officer Purchase at $0.51 - $0.51 per share. Direct 7,828 Dec 23, 2015 15,350

    GODIN ANDRE Officer Purchase at $0.50 - $0.51 per share. Direct 6,640 Dec 22, 2015 13,150

    GODIN ANDRE Officer Purchase at $0.50 - $0.5 per share. Direct 3,250 Dec 21, 2015 6,500
     
  3. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    Here is one of the reason why i like this stock so much is because of this thin-flim version of the Blockbuster Cialis which works faster than tablet . There are NO generics available on the Markets so IGXT could capture a significant market share with their better version . NDA submission expected in 4Q and FDA approval late 2017 .This Drug alone is worth more than $2 per share and they have a full Pipeline of Drugs which are close to Market entry .


    Product :Tadalafil (Erectile Dysfunction)
    •505(b)(2) USA NDA submission in Q4/2016
    •Expected USA launch Q4/2017


    Wafer Viagra For Instant Results One of the big challenges for erectile dysfunction medicine manufacturers is to quicken the time between the application of the medicine and its response. Men want instant results when they take Viagra, Cialis or Levitra and complain that having to wait as much as thirty minutes before the active ingredient is effective can burst the bubble of spontaneity and passion which are often essential requirements of good sex. Well a solution could be at hand following research done by a Canadian research company called IntelGenx who have developed wafers [like the common breath freshness ones] that are designed to melt on your tongue which they say will get the medicine into your bloodstream around 30% faster than by using conventional tablets. IntelGenx say that because the mouth is lined with tiny blood vessels applying the wafer Viagra here can give a very fast application of the drug directly into the bloodstream. IntelGenx said that they would be conducting more clinical trials to corroborate this and they hoped to develop a whole range of fast acting wafer medications to treat not only erectile dysfunction but also pain relief, depression and hypertension. Sometimes men complain that if they have eaten a large meal it can take an even longer time for the Viagra, Cialis and Levitra to take effect. If on the other hand they made use of erectile dysfunction medication in a wafer form applied directly to the mouth and therefore bypassing their digestive system this problem would disappear. Using a wafer type of Viagra would also mean that you wouldn't have to go and get a glass of water in the middle of a passionate encounter in order to swallow your pill. Wafer Viagra would be a much more discreet application of impotence medication and Ukmedix News will be looking out for updates on the IntelGenx clinical testing done on this new idea
     
  4. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
  5. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    5,213
    Likes Received:
    1,085
    Let me get you a better chart

    [​IMG]
     
  6. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    Thanks for the Chart Gil ...


    Another IGXT Drug that is close to FDA approval and which has very attractive Market Potential .


    RIZAPORT ® for Migraines -Commercial Triptan Market Opportunity

    •RIZAPORT® likely to be the first thin film triptan to reach the U.S. market

    •Rizatriptan was selected as the drug to deliver via VersaFilm™ because it:

    1.Exhibits the highest efficacy data compared to all triptans

    2.Exhibits the shortest Tmax, indicating rapid onset of action, which is extremely important for migraine sufferers

    3.Highly effective in treatment of migraine attacks in children and adolescents. This sub-group together with the elderly could greatly benefit from RIZAPORT®

    •The worldwide market for anti-migraine drugs was estimated to reach approximately $1.7 billion in 2015, of which the sales of triptan drugs, the target market for RIZAPORT®, were estimated at approximately $697 million*

    •But the cost of producing RIZAPORT® is low, thus allowing for very high profit margins

    •An independent patient survey conducted by Brand Institute found that the majority of patients would be interested in RIZAPORT®
    if it becomes available and indicated that they are likely to ask
    their physician to prescribe migraine medication in an oral film formulation

    •A survey of physicians who treat migraine headaches was conducted and showed that a large majority of these would prescribe a film based migraine treatment
     
  7. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
  8. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    gettint closer and closerr to the $1 mark and stock is still brutally undervalued at laughable $40 million

    [​IMG]
     
  9. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    And up she goes again i love this stock . Market cap of $46 million still laughable for this undiscovered Goldmine
     
  10. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    Great News released Friday after hour , now they have a lot of Cash for 3 years but they could be already profitable by next year .

    IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million....August 05, 2016
    http://www.intelgenx.com/investors/...orfivo-XLR-Royalty-for-6-Million/default.aspx



    The Drug Montelukast mentioned below in the article alone is worth multiple times the current market cap of laughable $46 Million .If everything goes well with the potential Blockbuster Drug then IGXT will be the next Billion Dollar Company .With the large Pipeline they have and the terrible brutally low Valuation this stock is a Lifetiime opportunity .GL


    The wonder pill that could STOP your brain ageing: Common asthma drug may be a cure for Alzheimer's, claims study
    http://www.dailymail.co.uk/sciencet...sthma-drug-cure-Alzheimer-s-claims-study.html


    IntelGenx to Initiate Phase 1 Trial of Montelukast
    http://www.intelgenx.com/investors/...ate-Phase-1-Trial-of-Montelukast/default.aspx

    IntelGenx expects results from the phase 1 trial to be available in September 2016. Following the completion of the phase 1 results, the Company will begin preparation work to initiate a phase 2 study where patients will be enrolled. IntelGenx will be actively seeking a partnership or alliance opportunity to complete the remaining developmental work and commercialization of this product.

    "Montelukast is by far the most important and promising drug repurposing opportunity that the company has in its product pipeline," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "IntelGenx with Dr. Aigner, is taking a leadership position in this most serious unmet need affecting millions globally. The market for degenerative diseases of the brain is a multi-billion-dollar opportunity for the company. We look forward to communicating the results from the phase 1 study and advancing montelukast forward to reach its full potential."
     
  11. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    Shorts tried hard to kill momentum yesterday but they will lose the Game because the Stock is terrible Undervalued und there is to much News on the way so every dip below $1 is a great buying opportunity .


    IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus.....Tuesday, 09 Aug 2016
    http://www.insiderfinancial.com/int...rp-otcmktsigxt-is-todays-pharma-focus/116698/


    Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it. We’ll know more after the markets close on August 11th when the company reports second quarter results and provides an update on the earnings call.
     
  12. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    The Company has now Cash untill mid 2018 excluding Upfront Payments from new Partnerships and Product Revenues . Partnerdeal news and Phase 1 Results of their Alzheimer Drug coming within 6 Weeks . Market Cap still way below $50 Million which is still a big Joke .

    from yesterdays 2Q Results
    http://www.intelgenx.com/investors/...-and-Appointment-of-New-Director/default.aspx

    Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016

    Initiated a phase 1 study of Montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia.IntelGenx expects results from the phase 1 trial to be available in September 2016.
     
  13. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    A lot of new Partnerdeals on the way which means Upfront Payments to the Company . Market Cap of $43 Million is still laughable for this Goldmine .GL


    Transcript Q2 released last Thursday
    http://s2.q4cdn.com/790425727/files...nx-q2-2016-financial-results-47950179-v.3.pdf

    With respect to other BD activities, we're clearly focusing right now in the business development area on bringing in new deals. For example at the recent BIO Conference, we met with 50 different pharmaceutical companies to discuss partnering opportunities, and we're currently in discussions with eight companies that are interested in RIZAPORT licenses, 17 companies that are interested in our Tadalafil product, three companies are interested in our schizophrenia drug, and five companies have expressed interest in a deal on Forfivo outside of the US.

    Above and beyond that, there are ongoing late-stage discussions with a global pharmaceutical company for multiple products with the potential goal of finalizing a definitive agreement in the third quarter of 2016
    .
     
  14. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
  15. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
  16. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    GREAT NEWS OUT .. and stock is stiill terrible underpriced at a market cap of laughable $52 Million .GL

    http://www.intelgenx.com/investors/...generative-Diseases-of-the-Brain/default.aspx

    IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
    August 22, 2016

    "We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm™ significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm™ technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
     
  17. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
  18. Edson wag

    Edson wag Member

    Joined:
    Apr 6, 2016
    Messages:
    82
    Likes Received:
    6
    From the relationship between price and moving averages; we can see that: this stock is BULLISH in short-term; and BULLISH in mid-long term. Looking for breakout at 0.9 with a short term target of 1.05.
    http://www.allotcbb.com/quote.php?symbol=igxt
     
  19. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5
    Pullback creates a fantastic buying opp ..Partner deal news is around the corner

    •Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
     
  20. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    126
    Likes Received:
    5

Share This Page